The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wednesday.
PTC's Q4 performance is driven by steady growth in recurring revenues amid a tough sales backdrop.
PTC Inc. (PTC) Q4 2024 Earnings Call Transcript
Although the revenue and EPS for PTC Inc. (PTC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
PTC Inc. (PTC) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.20 per share a year ago.
Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in demand for its industrial design and testing software as companies keep a tight leash on budgets.
PTC's fiscal fourth-quarter performance is likely to have been driven by strong business momentum across PLM and CAD segments amid forex fluctuations.
Evaluate the expected performance of PTC Inc. (PTC) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PTC Inc. (PTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Inc. PTC has inked a Strategic Collaboration Agreement with Amazon Web Services (“AWS”) to boost the growth of its Onshape solution. This collaboration aims to enhance Onshape's capabilities, promote customer adoption and advance AI initiatives, all intended to help designers and engineers create high-quality products more swiftly and efficiently.
Roblox is posting very strong growth, but its stock still trades far below its previous high. Despite challenging end-market trends, software company PTC keeps generating double-digit growth in its key metric.
PTC Therapeutics, Inc. achieved dose-dependent lowering of mutant Huntingtin protein in both the blood and CSF of HD patients, using 5 mg and 10 mg of PTC518. The global Huntington's Disease treatment market is expected to reach $3.06 billion by 2033. NDA of sepiapterin for the treatment of patients with phenylketonuria submitted July 2024.